T-DXd

T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

by
T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

Trastuzumab deruxtecan ( T-DXd , DS-8201 ) has a clinical incidence of interstitial lung disease (ILD) of approximately 10-15%. The mechanism of occurrence is not due to a single factor, but rather an interaction between target-dependent and non-target-dependent pathways. Firstly, the target-dependent mechanism arises from the low expression levels of HER2 in alveolar epithelial cells … Read more

Strategic Planning in ADC Development: How to Innovate in the Crowded HER2 ADC Space?

by
Strategic Planning in ADC Development: How to Innovate in the Crowded HER2 ADC Space?

The emergence of T-DXd represents a significant breakthrough in the treatment of HER2-positive and HER2-low expressing breast cancer. However, like any effective anti-cancer therapy, acquired resistance remains a major challenge affecting the long-term benefits for patients. Since the launch of Trastuzumab emtansine in 2013, five HER2 ADCs have been approved:Table 1: Approved HER ADCsAs clinical … Read more

A New Chapter in ESMO: Professor Yang Qingmo Analyzes Innovations in ADC Drug Therapy, Opening New Horizons for HR+ MBC Treatment

by
A New Chapter in ESMO: Professor Yang Qingmo Analyzes Innovations in ADC Drug Therapy, Opening New Horizons for HR+ MBC Treatment

*For reference by medical professionals only ADC drugs reshape the stratified treatment strategy for HR+ advanced breast cancer In recent years, the rapid development of antibody-drug conjugates (ADC) has brought groundbreaking progress to the treatment of advanced breast cancer.Trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd) are representative drugs that are profoundly changing the treatment landscape … Read more

Available ADC Drugs for Breast Cancer Patients

by
Available ADC Drugs for Breast Cancer Patients

IntroductionIn the field of breast cancer treatment, antibody-drug conjugates (ADC) are gradually becoming an important therapeutic approach.ADC drugs are a new type of cancer treatment that combines the targeting capability of antibodies with the potent killing power of chemotherapy drugs, allowing for precise delivery of chemotherapy agents to cancer cells, thereby improving efficacy and reducing … Read more

Management of Adverse Reactions to ADC Drugs in Breast Cancer

by
Management of Adverse Reactions to ADC Drugs in Breast Cancer

Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more

Standards and Guidelines for ADC Drug Infusion

by

* For reference by medical professionals only What Issues Should Be Addressed During the Infusion of ADC Drugs for Breast Cancer? ADC drugs combine the precise targeting of antibody drugs with the efficient killing advantage of cytotoxic drugs, gradually changing the treatment landscape for breast cancer. Currently, ADC drugs that have entered clinical practice in … Read more

Overview of ADC Drugs for Breast Cancer

by
Overview of ADC Drugs for Breast Cancer

As early as 1913, during the 17th International Medical Congress, Professor Paul Ehrlich proposed the concept of the “magic bullet”, using monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, thereby achieving the goal of killing tumor cells. With the development of monoclonal antibody production technology and the exploration of antibody conjugates, antibody-drug conjugates … Read more